Collaborate Rather Than Compete: Korea’s Push Toward A Biopharma Powerhouse
Industry Begins To Take Collective Moves
Executive Summary
Korean biopharma companies and the government are making diverse efforts to collaborate and seek growth to overcome limited resources and capital, as well as a tough investment environment.
You may also be interested in...
Japan’s Largest Biocluster, Korean Ventures To Collaborate For Cell And Gene Therapies
Japan’s largest biopharma R&D hub has been in active discussions with Korean bioventures for possible collaboration in the cell and gene therapy area. The idea, also backed by the Korean government, started with a paradigm shift during the pandemic.
Deal Watch: Japan’s SNBL To Re-Absorb US Spinout Satsuma
Shin Nippon Biomedical Laboratories would take over migraine candidate STS101, now under FDA review. Blue Water Vaccines to pick up BPH drug from Veru.
Dong-A ST Faces New Wave Of Change As It Challenges Norms
Dong-A ST’s president of R&D Jae-Hong Park talks to Scrip about the changes needed in the domestic pharma sector and wider industry if Korean biopharma firms are to step up to global levels.